Drug Details
| General Information of the Drug (ID: DR7304) | ||||
|---|---|---|---|---|
| Name |
ABT-263
|
|||
| Synonyms |
Navitoclax; ABT 263; S1001_Selleck; ABT263, Navitoclax; 4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({4-({(1R)-3-morpholin-4-yl-1-[(phenylsulfanyl)methyl]propyl}amino)-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide
Click to Show/Hide
|
|||
| Molecular Type |
Small molecule
|
|||
| Disease | Chronic lymphocytic leukaemia [ICD-11: 2A82] | Phase 2 | [1] | |
| Structure |
|
Click to Download Mol2D MOL |
||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
| Formula |
C47H55ClF3N5O6S3
|
|||
| PubChem CID | ||||
| Canonical SMILES |
CC1(CCC(=C(C1)CN2CCN(CC2)C3=CC=C(C=C3)C(=O)NS(=O)(=O)C4=CC(=C(C=C4)NC(CCN5CCOCC5)CSC6=CC=CC=C6)S(=O)(=O)C(F)(F)F)C7=CC=C(C=C7)Cl)C
|
|||
| InChI |
1S/C47H55ClF3N5O6S3/c1-46(2)20-18-42(34-8-12-37(48)13-9-34)36(31-46)32-55-22-24-56(25-23-55)39-14-10-35(11-15-39)45(57)53-65(60,61)41-16-17-43(44(30-41)64(58,59)47(49,50)51)52-38(19-21-54-26-28-62-29-27-54)33-63-40-6-4-3-5-7-40/h3-17,30,38,52H,18-29,31-33H2,1-2H3,(H,53,57)/t38-/m1/s1
|
|||
| InChIKey |
JLYAXFNOILIKPP-KXQOOQHDSA-N
|
|||
| CAS Number |
CAS 923564-51-6
|
|||
| GDSC | ||||
| TTD Drug ID | ||||
| DrugBank ID | ||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
| Apigenin | Psilotum nudum | Click to Show/Hide the Molecular Data of This NP | ||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | ERK2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | FOXO3 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | NCI-H1975 | CVCL_1511 | Lung adenocarcinoma | Homo sapiens | ||
| HCC827 | CVCL_2063 | Lung adenocarcinoma | Homo sapiens | |||
| NCI-H1650 | CVCL_1483 | Lung adenocarcinoma | Homo sapiens | |||
| NCI-H3255 | CVCL_6831 | Lung adenocarcinoma | Homo sapiens | |||
| SK-MEL-28 | CVCL_0526 | Cutaneous melanoma | Homo sapiens | |||
| Experimental
Result(s) |
Apigenin upregulated the expression of Noxa in EGFRm tumor cells by targeting the AKT-FoxO3a pathway, thereby synergizing with ABT-263 to suppress tumor cell growth and proliferation in vitro and in vivo. | |||||
| β. A List of Natural Product(s) Able to Decrease the Adverse Effect of This Drug | ||||||
| Wogonin | Scutellaria amoena | Click to Show/Hide the Molecular Data of This NP | ||||
| Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [3] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | MCL1 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | ARAC-8C | CVCL_GZ09 | T acute lymphoblastic leukemia | Homo sapiens | ||
| MOLT-4 | CVCL_0013 | Adult T acute lymphoblastic leukemia | Homo sapiens | |||
| Jurkat | CVCL_0065 | T acute lymphoblastic leukemia | Homo sapiens | |||
| KM-H2 | CVCL_1330 | Hodgkin lymphoma | Homo sapiens | |||
| In-vivo Model | Immunodeficient mice (Rag2-/-/II2rg-/-) were implanted subcutaneously in the dorsal flank region with CEM (5*107 cells). | |||||
| Experimental
Result(s) |
Wogonin potentiates the lethality of ABT-263 in ABT-263-resistant cancer cells and wogonin reduces the effective dose of ABT-263 thereby possibly decreasing the risk of adverse side effects. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Apoptosis regulator Bcl-2 (BCL-2) | Molecule Info | [4] | |
| Apoptosis regulator Bcl-W (BCL-W) | Molecule Info | [4] | ||
| Apoptosis regulator Bcl-xL (BCL-xL) | Molecule Info | [4] | ||
| G1/S-specific cyclin-D1 (CCND1) | Molecule Info | [5] | ||
| KEGG Pathway | MicroRNAs in cancer | Click to Show/Hide | ||
| 2 | FoxO signaling pathway | |||
| 3 | Cell cycle | |||
| 4 | p53 signaling pathway | |||
| 5 | PI3K-Akt signaling pathway | |||
| 6 | AMPK signaling pathway | |||
| 7 | Wnt signaling pathway | |||
| 8 | Hippo signaling pathway | |||
| 9 | Focal adhesion | |||
| 10 | Jak-STAT signaling pathway | |||
| 11 | Prolactin signaling pathway | |||
| 12 | Thyroid hormone signaling pathway | |||
| 13 | Oxytocin signaling pathway | |||
| 14 | Hepatitis B | |||
| 15 | Measles | |||
| 16 | HTLV-I infection | |||
| 17 | Pathways in cancer | |||
| 18 | Viral carcinogenesis | |||
| 19 | Proteoglycans in cancer | |||
| 20 | Colorectal cancer | |||
| 21 | Pancreatic cancer | |||
| 22 | Endometrial cancer | |||
| 23 | Glioma | |||
| 24 | Prostate cancer | |||
| 25 | Thyroid cancer | |||
| 26 | Melanoma | |||
| 27 | Bladder cancer | |||
| 28 | Chronic myeloid leukemia | |||
| 29 | Acute myeloid leukemia | |||
| 30 | Small cell lung cancer | |||
| 31 | Non-small cell lung cancer | |||
| 32 | Viral myocarditis | |||
| 33 | NF-kappa B signaling pathway | |||
| 34 | HIF-1 signaling pathway | |||
| 35 | Sphingolipid signaling pathway | |||
| 36 | Protein processing in endoplasmic reticulum | |||
| 37 | Apoptosis | |||
| 38 | Adrenergic signaling in cardiomyocytes | |||
| 39 | Neurotrophin signaling pathway | |||
| 40 | Cholinergic synapse | |||
| 41 | Amyotrophic lateral sclerosis (ALS) | |||
| 42 | Toxoplasmosis | |||
| 43 | Tuberculosis | |||
| 44 | Epstein-Barr virus infection | |||
| 45 | Ras signaling pathway | |||
| 46 | Transcriptional misregulation in cancer | |||
| NetPath Pathway | TCR Signaling Pathway | Click to Show/Hide | ||
| 2 | IL2 Signaling Pathway | |||
| 3 | EGFR1 Signaling Pathway | |||
| 4 | TGF_beta_Receptor Signaling Pathway | |||
| 5 | Notch Signaling Pathway | |||
| 6 | Wnt Signaling Pathway | |||
| 7 | IL5 Signaling Pathway | |||
| 8 | IL3 Signaling Pathway | |||
| 9 | Leptin Signaling Pathway | |||
| 10 | RANKL Signaling Pathway | |||
| 11 | TSLP Signaling Pathway | |||
| Panther Pathway | Apoptosis signaling pathway | Click to Show/Hide | ||
| 2 | PI3 kinase pathway | |||
| 3 | Wnt signaling pathway | |||
| 4 | CCKR signaling map ST | |||
| 5 | Oxidative stress response | |||
| Pathway Interaction Database | Direct p53 effectors | Click to Show/Hide | ||
| 2 | Notch signaling pathway | |||
| 3 | Coregulation of Androgen receptor activity | |||
| 4 | Validated transcriptional targets of AP1 family members Fra1 and Fra2 | |||
| 5 | Presenilin action in Notch and Wnt signaling | |||
| 6 | Integrin-linked kinase signaling | |||
| 7 | Regulation of Telomerase | |||
| 8 | E-cadherin signaling in the nascent adherens junction | |||
| 9 | ATF-2 transcription factor network | |||
| 10 | AP-1 transcription factor network | |||
| 11 | FOXM1 transcription factor network | |||
| 12 | Neurotrophic factor-mediated Trk receptor signaling | |||
| 13 | C-MYB transcription factor network | |||
| 14 | Validated nuclear estrogen receptor alpha network | |||
| 15 | Signaling mediated by p38-gamma and p38-delta | |||
| 16 | Regulation of nuclear beta catenin signaling and target gene transcription | |||
| 17 | Validated targets of C-MYC transcriptional repression | |||
| 18 | Trk receptor signaling mediated by PI3K and PLC-gamma | |||
| 19 | Regulation of retinoblastoma protein | |||
| 20 | Signaling events mediated by focal adhesion kinase | |||
| 21 | Role of Calcineurin-dependent NFAT signaling in lymphocytes | |||
| 22 | IL2-mediated signaling events | |||
| 23 | IL2 signaling events mediated by PI3K | |||
| 24 | Ceramide signaling pathway | |||
| 25 | RXR and RAR heterodimerization with other nuclear receptor | |||
| 26 | HIV-1 Nef: Negative effector of Fas and TNF-alpha | |||
| 27 | Caspase Cascade in Apoptosis | |||
| 28 | Signaling events mediated by Stem cell factor receptor (c-Kit) | |||
| 29 | EPO signaling pathway | |||
| 30 | IL2 signaling events mediated by STAT5 | |||
| 31 | IL3-mediated signaling events | |||
| Reactome | Pre-NOTCH Transcription and Translation | Click to Show/Hide | ||
| 2 | RMTs methylate histone arginines | |||
| 3 | Ubiquitin-dependent degradation of Cyclin D1 | |||
| 4 | Cyclin D associated events in G1 | |||
| 5 | Activation of BAD and translocation to mitochondria | |||
| 6 | BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members | |||
| 7 | The NLRP1 inflammasome | |||
| WikiPathways | Apoptosis | Click to Show/Hide | ||
| 2 | Apoptosis Modulation and Signaling | |||
| 3 | DNA Damage Response (only ATM dependent) | |||
| 4 | DNA Damage Response | |||
| 5 | Notch Signaling Pathway | |||
| 6 | G1 to S cell cycle control | |||
| 7 | Wnt Signaling Pathway and Pluripotency | |||
| 8 | TGF beta Signaling Pathway | |||
| 9 | Wnt Signaling Pathway Netpath | |||
| 10 | Copper homeostasis | |||
| 11 | Focal Adhesion | |||
| 12 | PPAR Alpha Pathway | |||
| 13 | Mesodermal Commitment Pathway | |||
| 14 | Hair Follicle Development: Organogenesis (Part 2 of 3) | |||
| 15 | Bladder Cancer | |||
| 16 | Pre-NOTCH Expression and Processing | |||
| 17 | S Phase | |||
| 18 | Polycystic Kidney Disease Pathway | |||
| 19 | Retinoblastoma (RB) in Cancer | |||
| 20 | Spinal Cord Injury | |||
| 21 | Integrated Pancreatic Cancer Pathway | |||
| 22 | Prostate Cancer | |||
| 23 | Signaling Pathways in Glioblastoma | |||
| 24 | IL-7 Signaling Pathway | |||
| 25 | Leptin signaling pathway | |||
| 26 | miR-targeted genes in muscle cell - TarBase | |||
| 27 | miR-targeted genes in lymphocytes - TarBase | |||
| 28 | miR-targeted genes in epithelium - TarBase | |||
| 29 | Integrated Breast Cancer Pathway | |||
| 30 | miRNAs involved in DNA damage response | |||
| 31 | miRNA Regulation of DNA Damage Response | |||
| 32 | Androgen receptor signaling pathway | |||
| 33 | Senescence and Autophagy in Cancer | |||
| 34 | IL-2 Signaling Pathway | |||
| 35 | FAS pathway and Stress induction of HSP regulation | |||
| 36 | Kit receptor signaling pathway | |||
| 37 | IL-3 Signaling Pathway | |||
| 38 | Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | |||
| 39 | Nanoparticle triggered autophagic cell death | |||
| 40 | Amyotrophic lateral sclerosis (ALS) | |||
| 41 | Corticotropin-releasing hormone | |||
| 42 | Interleukin-11 Signaling Pathway | |||
| 43 | miR-targeted genes in leukocytes - TarBase | |||
| 44 | Integrated Cancer pathway | |||
| 45 | Intrinsic Pathway for Apoptosis | |||
| 46 | TP53 Network | |||
| 47 | Influenza A virus infection | |||
| 48 | IL-5 Signaling Pathway | |||
| 49 | IL-6 signaling pathway | |||
| 50 | TNF alpha Signaling Pathway | |||